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Abstract
Background: Microsatellite-unstable colorectal cancers (CRC) that are due to deficient DNA mismatch repair (dMMR)
represent approximately 15% of all CRCs in the United States. These microsatellite-unstable CRCs represent a heterogenous
group of diseases with distinct oncogenesis pathways. There are overlapping clinicopathologic features between some of
these groups, but many important differences are present. Therefore, determination of the etiology for the dMMR is vital
for proper patient management and follow-up.
Main body: Epigenetic inactivation of MLH1 MMR gene (sporadic microsatellite-unstable CRC) and germline
mutation in an MMR gene (Lynch syndrome, LS) are the two most common mechanisms in the pathogenesis
of microsatellite instability in CRC. However, in a subset of dMMR CRC cases that are identified by screening tests, no
known LS-associated genetic alterations are appreciated by current genetic analysis. When the etiology for dMMR is
unclear, it leads to patient anxiety and creates challenges for clinical management.
Conclusion: It is critical to distinguish LS patients from other patients with tumors due to dMMR, so that the proper
screening protocol can be employed for the patients and their families, with the goal to save lives while avoiding
unnecessary anxiety and costs. This review summarizes the major pathogenesis pathways of dMMR CRCs, their
clinicopathologic features, and practical screening suggestions. In addition, we include frequently asked questions for
MMR immunohistochemistry interpretation.
Keywords: Mismatch repair protein, MMR, Lynch syndrome, Microsatellite instability, MSI, Colorectal cancer, Molecular
genetics, Immunohistochemistry
Background
Colorectal cancer (CRC) represents the third most
common malignancy diagnosed both in men and women
in the United States. Approximately 15% of CRC display
a defect in the mismatch repair pathway [1], resulting in
microsatellite instability (MSI). The identification of MSI
CRC from microsatellite-stable (MSS) tumors is clinically
important, because MSI tumors have a better stage-
adjusted survival compared to MSS tumors and may
respond differently to 5-fluorouracil-based adjuvant
chemotherapy [2]. In addition, it is important to identify
those patients with Lynch Syndrome (LS).
Defects in the mismatch repair (dMMR) mechanism
leads to the pathogenesis of MSI tumors. The MMR
mechanism identifies and fixes base-pair mismatches
that occur within the genome. Proteins within the MMR
system include MLH1, PMS2, MSH2, MSH6, MLH3,
MSH3, PMS1, and Exo1. These proteins form heterodi-
mers that repair DNA damage. The most common and
relevant heterodimers in colorectal carcinogenesis are
MLH1/PMS2 and MSH2/MSH6. Microsatellites, also
known as short tandem repeats, are composed of mono-
to hexa-nucleotides that constitute a repeated motif.
These microsatellites constitute up to 3% of the genome
and are variable in length. Chromosomal alleles often
contain different lengths of the same microsatellite. Due
to their repetitive nature, microsatellites are highly
susceptible to errors in MMR; therefore dMMR tumors
demonstrate microsatellite instability and are often
hyper- or ultra-mutated [3].
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MSI CRC identified by screening tests (MMR immu-
nohistochemistry, IHC, or polymerase chain reaction,
PCR) can be further divided into four categories after
additional testing [4] (also see Table 1):
(A) Sporadic dMMR – MLH1 promoter
hypermethylation: MSI CRC due to hypermethylation
of CpG islands in the MLH1 promoter (these tumors
often arise via the serrated pathway, harbor BRAF
mutation, and account for 10% to 15% of CRC);
(B) Lynch Syndrome due to germline mutations in one
of the MMR genes (MLH1, PMS2, MSH2, MSH6)
or alteration in EPCAM (TACSTD1) gene that causes
epigenetic silencing ofMSH2 [5] (these tumors often
arise in tubular adenomas and account for
approximately 3% of CRC);
(C)Unexplained dMMR Colorectal Cancers (sporadic
dMMR-somatic MMR mutation and others): Cases
with neither identified germline mutation of MMR
nor hypermethylation of the promoter region of
MLH1 (these cases have unexplained dMMR and
have been termed Lynch-like by some);
(D)Rarely, constitutional MMR deficiency syndrome
(biallelic germline MMR mutations; of note, the
normal adjacent tissue in these cases will also
have dMMR).
Main text
Sporadic dMMR colorectal cancers – MLH1 promoter
hypermethylation/CpG Island Methylator Phenotype
(CIMP)
Tumors that show DNA hypermethylation at multiple
promoters are classified as showing the CpG Island
Methylator Phenotype (CIMP). There are several types of
epigenetic alterations, including DNA hypermethylation,
that regulate gene expression. Promoter methylation
suppresses gene transcription by inhibiting binding of
transcription factors, affecting histone acetylation, and
altering conformations to effectively block access of tran-
scriptional machinery to the gene. Epigenetic silencing in
tumors is biologically equivalent to acquiring an inactivat-
ing mutation and may account for the first, second, or
both hits in silencing tumor suppressor genes. Genes that
are commonly hypermethylated in CRC include MLH1,
MCC (methylated in CRC), APC and MGMT. The
promoter region of five genes has been chosen as proxy
markers of CIMP: CACNA1G, IGF2, NEUROG1, RUNX3
and SOCS1 [6]. Hypermethylation of at least three
markers is the definition of CIMP. CRC with CIMP
frequently harbor BRAF mutations and show methylation
of MLH1 resulting in MSI in up to 70% of cases. Of
interest, the CDX2 negative/Cytokeratin 20 negative im-
munohistochemical phenotype defines a distinct subgroup
of MSI CRCs with poor differentiation, CIMP status, and
unfavorable prognosis [7].
Lynch syndrome
LS is an autosomal dominant disorder that increases the
risk of developing CRC and endometrial adenocarcinoma,
as well as tumors of the small intestine, stomach, ureter,
renal pelvis, ovary, brain, prostate [8], among others. LS is
a result of deleterious germline mutations in the genes
associated with DNA MMR (MLH1, PMS2, MSH2, MSH6
and EPCAM). Cancers (such as CRC) arise when a second
hit occurs in the unaffected wild type allele, through
various mechanisms such as loss of heterozygosity, muta-
tion, or hypermethylation. Most (90%) CRC due to LS
have MSI due to the defective MMR mechanisms caused
by the germline mutation in association with the second
hit. It is the most common hereditary CRC syndrome,
with approximately 2–5% of all CRCs due to LS. Patients
with LS benefit from increased surveillance; therefore,
identification of patients as well as family members with
this syndrome is very important. Historically, these cases
were grouped with other familial CRC cases and referred
to as Hereditary Nonpolyposis Colorectal Cancer
(HNPCC). The term HNPCC is no longer preferred due
to observations that patients with LS do have adenoma-
tous polyps and these adenomatous polyps are more likely
to progress to CRC [9].
Table 1 Comparison of microsatellite-unstable colorectal cancers
(A)










Germline mutation None One allele of a MMR gene
(MLH1, PMS2, MSH2, MSH6)
None Both alleles of a MMR gene
(MLH1, PMS2, MSH2, MSH6)
Somatic mutation BRAF V600E 2nd allele of the mutated
MMR gene
Both alleles of a MMR gene
(MLH1, PMS2, MSH2, MSH6)
None
Epigenetic alteration Somatic biallelic promoter
methylation of MLH1
Germline deletion in 3′ end
of EPCAM leads to MSH2
methylation
None None
Intense Lifelong Screening No Yes No Yes
Abbreviations: dMMR mismatch repair deficiency, MMR mismatch repair
Adapted from Carethers and Stoffel [4]
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The Amsterdam criteria were initially developed in
1990 [10] and later revised to Amsterdam II criteria in
1998 [11], to help identify families likely to have HNPCC
for research purposes by using personal and family
histories. The Amsterdam criteria include a series of
clinical criteria that are also known as the “3-2-1” rule
(Table 2). The Bethesda guidelines were developed in
1997 to identify patients who should have tumor screen-
ing for LS [12]. The revised Bethesda guidelines
proposed in 2004 [13] incorporated histologic compo-
nents into the screening guidelines. A comparison of the
Amsterdam criteria and the revised Bethesda criteria is
detailed in Table 2. Unfortunately, a significant portion
of CRC patients with LS were still missed when using
these criteria alone without MMR IHC or PCR testing
[14]. Therefore, it is currently recommended that all
newly diagnosed patients with CRC undergo LS screen-
ing by IHC and/or MSI PCR testing as recommended by
many authoritative organizations, including the Evalu-
ation of Genomic Applications in Practice and Preven-
tion (a working group sponsored by the Centers for
Disease Control and Prevention) in 2009 [15], the
National Comprehensive Cancer Network in 2014 [16],
the US Multi-Society Task Force in 2014 [17], the
American College of Gastroenterology [18] and the
American Society of Clinical Oncology [19] in 2015.
Patients who have clinical features concerning for LS,
but whose screening results indicate microsatellite stabil-
ity, should be further evaluated by another technique
such as MSI PCR (if initial screening was by IHC
staining) or IHC for the MMR proteins (if initial screen-
ing was by MSI molecular testing), or possibly genetic
sequencing of MMR genes since the sensitivity of the
MSI by PCR and IHC is not 100%.
Phenotypic variation in LS
The clinical presentation of a patient with LS can vary
depending on the MMR gene affected in the germline.
Patients with MLH1 mutations typically present with
classic LS (CRC as the first presenting symptom with a
mean age of 43 to 46). Similarly, patients with MSH2
mutations also present with classic LS, however these
patients are also at increased risk of extra-colonic
cancers. Muir-Torre syndrome, which is a rare variant of
LS in which patients develop hair follicle and sebaceous
gland neoplasms, have MSH2 germline mutations.
Patients with germline mutations in MSH6 are more
likely to develop endometrial cancer and may not test
positive for MSI by PCR. Mutations in PMS2 tend to
develop CRC at an older age compared to classic LS.
The rare biallelic mutation in any of the four MMR
genes (constitutional mismatch repair deficiency syndrome)
manifests as very early-onset (pediatric) hematological,
colorectal, urinary tract and brain (glioblastoma) cancers,
and neurofibromatosis [9].
Unexplained dMMR colorectal cancers (sporadic dMMR-
somatic MMR mutation and others)
This is an ill-defined group of MSI CRC patients who
have discordant screening and germline results. In these
Table 2 Comparison of the Amsterdam criteria, Amsterdam II criteria, and the revised Bethesda criteria
Amsterdam criteria
(meet all sub criteria)
Amsterdam II criteria
(meet all sub criteria)
Revised Bethesda criteria
(meet one of the following sub criteria)
3 or more relatives with histologically
confirmed colorectal cancer
3 or more relatives with Lynch syndrome-
associated cancer (colorectal cancer or
cancer of the endometrium, small
intestine, ureter or renal pelvis); cancers
are histologically verified
Colorectal cancer diagnosed in a patient
aged <50 years
2 or more successive generations
involved
2 or more successive generations affected Presence of synchronous, metachronous
colorectal cancer or other Lynch syndrome-
related tumors: cancer of the colorectum,
stomach, small intestine, pancreas, biliary
tract, renal pelvis, ureter, ovary, brain;
sebaceous gland adenoma or carcinoma
and keratoacanthoma, regardless of age
1 or more of the cancers diagnosed
before age 50 years
1 or more relatives diagnosed before
the age of 50 years
Colorectal cancer with MSI phenotype,
especially lymphocyte infiltration,
diagnosed in a patient aged <60 years
One should be a first-degree relative
of the other two
One should be a first-degree relative
of the other two
Patient with colorectal cancer and a
first-degree relative with a Lynch
syndrome-related tumor, with one of





should be excluded in cases of
colorectal carcinoma
Patient with colorectal cancer with two
or more first-degree or second-degree
relatives with a Lynch syndrome-related
tumor, regardless of age
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cases, the initial screening for LS is positive (either
abnormal MMR IHC or MSI PCR); however, BRAF
V600E PCR and/or MLH1 promoter hypermethylation
studies does not indicate sporadic CRC, and genetic
sequencing for MMR genes do not identify a germline
mutation. These unexplained dMMR cases have been
referred to as “Lynch-like syndrome” in the literature,
however the causes for these cases are heterogenous and
Lynch-like is a misleading nomenclature.
Recent studies have elucidated some of the causes/er-
rors that could make a tumor look like a sporadic
dMMR tumor. Approximately 70% of these patients may
have biallelic somatic mutations in the MMR gene [20–22].
These patients with biallelic somatic mutations do not carry
a germline mutation in MMR genes and therefore their
progeny are not at risk of LS, and do not need lifelong
intense screening protocol like LS patients.
Other potential explanations for unexplained dMMR
cases [23] include: (a) incorrect performance/interpret-
ation of MMR IHC results (absence of nuclear staining
due to technical limitations or professional misinterpre-
tations) (20%); (b) failure to detect germline MMR gene
alteration using currently available tests (such as inver-
sion of MSH2 exons 1 to 7 that is not tested by many
commercial labs) (unknown%); (c) other germline gene
defects that also cause MSI phenotype, such as biallelic
MUTYH mutation (3%) [24–26]; (d) somatic mosaicism
(<1%) [27–29]; (e) constitutional epimutation of MLH1
(germline monoallelic hypermethylation of the MLH1
promoter region; no alteration to the genetic sequence
of MLH1) (<1%) [30–32].
Constitutional mismatch repair deficiency syndrome
(CMMRD)
CMMRD patients have germline mutation of both
alleles of a MMR gene (MLH1, PMS2, MSH2, MSH6),
leading to loss of expression of the corresponding
MMR protein. Unlike LS, CMMRD patients show loss
of MMR staining in both the tumor and the back-
ground non-neoplastic tissue.
Clinicopathologic features of MSI CRC
Clinically, tumors with MSI are more common in the
right colon [33]. Sporadic tumors typically occur in older
female patients, whereas, CRC in the context of LS often
occurs in younger patients (50 years of age or less).
These tumors respond poorly to 5-fluorouracil based
chemotherapies [34–36], but patients with MSI tumors
have a better prognosis than those with stage- matched
MSS tumors [37–40].
Microscopically, MSI tumors share similar histomor-
phology regardless of their respective pathogenesis. They
frequently have a mucinous phenotype, and are either
very well-differentiated or poorly differentiated. The
presence of signet ring cells or a medullary phenotype is
also frequently seen in this context. Intratumoral hetero-
geneity (mixed conventional, mucinous, and poorly
differentiated carcinoma) is common. The “dirty necrosis”
seen in microsatellite-stable colon cancers is frequently
absent. Tumors often contain increased intratumoral
lymphocytes, and may have a Crohn’s -like reaction with
prominent lymphoid aggregates at the periphery of the
tumor [13, 41–43].
The histologic features of germline and sporadic MSI
tumors are similar, although finding an adjacent sessile
serrated adenoma as the precursor lesion is more sug-
gestive of a sporadic tumor. In contrast, the precursor
lesion associated with LS is a tubular adenoma. A recent
study by Mas-Moya et al [44] demonstrated that when
compared to LS, Lynch-like syndrome is more likely to
occur in the right colon (a subset of LS tumors occurs at
left colon [45]), more often identified in patients with
tumors that harbor concurrent MLH1/PMS2 loss (with
lack of MLH1 promoter hypermethylation) or concurrent
MSH2/MSH6 loss, and less likely to have synchronous or
metachronous LS-associated cancers.
The prognosis of patients with CRC associated with
LS and MLH1 promoter hypermethylation appear to be
similar [46]. In up to 70% of CRC with hypermethylation
of the MLH1 promoter, there is a BRAF V600E gene
mutation. CRC patients with BRAF V600E mutation
have been shown to have a limited clinical response to
epidermal growth factor receptor (EGFR) targeted
therapies (cetuximab or panitumumab). Recent studies
indicated that therapies targeting the PD-1 immune
checkpoint blockade are effective in treating dMMR
CRC [47].
Screening for MSI and LS
Screening for MMR function can be done using IHC for
the MMR proteins, and/or MSI analysis by polymerase
chain reaction (PCR).
MMR protein expression by IHC is performed to
detect the absence or loss of a particular protein within
the nucleus of the tumor cells; abnormal IHC correlates
strongly with MSI status by PCR. MMR proteins are
normally present in many human cells, particularly in
proliferating cells such as crypt epithelium. Understanding
the biochemistry/molecular biology of MMR proteins is
important in the interpretation of IHC results. The most
common mutations found in LS are frameshift or non-
sense mutations that cause protein truncation or increased
degradation. These mutations result in absence/loss of the
mutated protein, which is easily detected by IHC. The
MMR proteins MLH1, PMS2, MSH2 and MSH6 form
heterodimer pairs in vivo (MLH1/PMS2 (MutLalpha) and
MSH2/MSH6 (MutSalpha)). When either MLH1 or
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MSH2 is mutated and degraded in vivo, this will cause
subsequent degradation and protein loss of its partner
PMS2 or MSH6, respectively. For instance, whenMSH2 is
mutated, this will appear immunohistochemically as
absence/loss of MSH2 and MSH6. However, the opposite
situation is not typically found. When either germline
PMS2 or MSH6 is mutated and therefore degraded in
vivo, there is usually no concomitant loss of protein
expression of MLH1 or MSH2, respectively. This is due to
the compensatory effects of other MMR proteins such as
MSH3, which can bind to, and stabilize, either MLH1 or
MSH2. Tumors that show absence of MSH2 and/or
MSH6 or PMS2 are suspicious for LS, and these patients
should be considered for sequencing of whatever protein
was missing (after proper consent). If a germline mutation
is then identified, this is diagnostic of LS. If a germline
mutation is not identified, somatic MMR gene and/or loss
of heterozygosity testing may be considered.
MSI by PCR evaluates tumors by amplifying microsatel-
lite repeats. The most widely used panel, the Bethesda
panel, consists of five microsatellite repeats, including 2
mononucleotide repeats (BAT25 and BAT26) and 3
dinucleotide repeats (D2S123, D5S346, and D17S250)
[48]. Microsatellites demonstrating at least two novel
alleles (shift) define MSI high (considered to be micro-
satellite unstable). MSI low is defined as the detection of
only one unique (shifted) microsatellite, although the
significance of this category is controversial. When no
shifted microsatellites are identified, this is defined as
MSS. If MSI analysis is used as the initial screening test
rather than IHC, BRAF mutational testing or MLH1 pro-
moter methylation can be used as the second step prior
to genetic sequencing in patients found to have MSI.
Either MMR IHC or MSI by PCR works well for
screening most cases, but each has limitations. IHC labs
are much more widely available than molecular labs, but
IHC results may be more affected by tissue fixation
conditions. MSI analysis requires normal tissue in
addition to tumor tissue for comparison, and may
require tumor microdissection, but is not typically
affected by fixation. Individual laboratories and multidis-
ciplinary teams ultimately must determine for them-
selves which technique(s) is most effective in their
institution. This issue may become less important with
the advent of next generation sequencing panels [49], in
which the cost for testing for all the MMR genes may in
some laboratories be similar to testing for a one single
MMR gene. Of note, MSI by PCR and MMR by IHC
rarely may miss MSH6 mutations, because MSH6
mutations are often MSI-low or MSS. This is a known
pitfall in MSI testing for gynecologic cancers given a
larger proportion of endometrial cancers harbor MSH6
mutations compared to CRC.
Approximately 5 to 10% of all CRC have substitution
of valine with glutamic acid at amino acid position 600
of BRAF. BRAF is a protein in the mitogen active pro-
tein kinase pathway and acts as a serine/threonine
kinase. The BRAF V600E mutation causes constitutive
activation of the kinase and increases MAP kinase
signaling. CRC with BRAF mutations are more com-
monly found in the right colon, have a high histologic
grade, show female predominance, and more frequently
originate from serrated polyps. Importantly, BRAF
V600E mutations are almost never found in LS, but are
seen in 40–76% of sporadic MSI CRCs. Therefore, in
screening algorithms for patients with CRC, analysis of
BRAF is a cost-effective method to screen for patients
who should undergo further genetic testing for LS rather
than gene sequencing in all those with absence of MLH1
and PMS2 [50, 51].
Besides being useful in distinguishing sporadic CRCs
from LS, BRAF V600E also has prognostic value, as
mutations have been suggested to be associated with a
worse outcome in MSS CRC. It may also predict resist-
ance to EGFR mediated antibodies [52]. Since BRAF and
KRAS are part of the same MAP kinase pathway, it is
not surprising that BRAF V600E mutations are almost
mutually exclusive of KRAS mutations. Of note, BRAF
mutation testing has no role in many extracolonic
LS-associated cancers, including endometrial and ovarian
cancers [53].
In patients with MLH1-deficient CRC, direct testing of
MLH1 promoter hypermethylation and/or BRAF V600E
mutational analysis, may be a cost-effective means of
identifying patients with sporadic tumors for whom
germline genetic testing is not indicated.
Figure 1 demonstrates the algorithm we currently use
for screening newly diagnosed CRC for LS. Initially, the
cancer is immunostained for MLH1, MSH2, MSH6, and
PMS2. When all four proteins are present, no further
work up is necessary unless there is specific clinical
concern. When MLH1 and PMS2 are absent by IHC,
the next step is analysis of BRAF by either PCR or IHC
[50, 51, 54, 55] to help determine if the patient has a
sporadic tumor or should be further evaluated for LS.
We use PCR rather than IHC for BRAF. If BRAF V600E
mutation is found, no further testing is required, as the
tumor is presumed to be sporadic CRC. If no BRAF
mutation is detected, the subsequent step depends on
the degree of suspicion of LS based on the patient’s age
and history. If there is suspicion of LS, the tumor will be
sent for genetic sequencing of MLH1 or PMS2.
Conversely, if there is low suspicion of LS, MLH1
promoter hypermethylation is then analyzed. If MLH1
promoter hypermethylation is not detected, the patient
will be sent for sequencing of MLH1 or PMS2. Some
laboratories use MLH1 methylation testing rather than
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BRAF mutational analysis after IHC in those tumors
found to have absence of MLH1 and PMS2. Similar to
BRAF mutated cases, those with MLH1 methylation are
presumed to represent sporadic tumors and do not need
to undergo further molecular testing for LS.
Practical guide for MMR IHC interpretation
MMR sensitivity and specificity
MMR IHC has good sensitivity for MSI-high tumors
(>90%) [56–59]; however it suffers lower sensitivity for
MSI-low tumors. In terms of specificity, MMR IHC is
efficient in detecting LS with MSH2 and MSH6 muta-
tion; however specificity for MLH1 and PMS2 is low due
to MLH1 hypermethylation [60, 61]. MLH1 and PMS2
often show loss of expression in sporadic CRC due to
transcriptional silencing of MLH1 by promoter
hypermethylation.
MMR staining patterns
Most cases screened with MMR IHC show typical pat-
terns of staining and the interpretation is relatively straight
forward. MMR proteins function in the cell nuclei,
therefore the staining pattern is nuclear. However,
punctate/speckled nuclear staining and nuclear mem-
brane staining are considered abnormal staining pat-
terns that should not be interpreted as preserved
MMR protein expression [23]. They either represent
loss of expression or staining artifact and therefore
warrant additional investigation (compare staining to
the internal control, repeat on a different block or
sample, or MSI by PCR).
It is important to point out that it is common to see
patchy (intratumoral heterogeneity) MMR staining in
MSS tumors. Tissue hypoxia and fixation issues have
been implicated for the staining heterogeneity [62, 63].
No definite consensus is present regarding the minimal
Fig. 1 Algorithm for screening newly diagnosed colorectal carcinoma (CRC) for Lynch syndrome (LS). The initial step is to screen cases using
immunohistochemistry (IHC) for mismatch repair proteins. When MLH1 and PMS2 are absent, the subsequent step is to utilize BRAF analysis by
polymerase chain reaction (PCR) or immunohistochemistry
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percentage of positive nuclei to be present to indicate
preserved/intact expression. In our practice, if more than
5% tumor nuclei show unequivocal nuclear staining
(some use >10% [23], or any convincing staining [64]), it
is considered normal/intact staining pattern. However, if
less than but close to 5% tumor nuclei are positive, re-
peating the stain is the next step. If the repeat is similar,
the stain result is considered equivocal and additional
testing (MSI by PCR or genetic) is suggested. Of note,
one needs to always make sure the positive internal con-
trol (stromal cells, lymphocytes, or nonneoplastic epithe-
lial cells), shows nuclear positivity, before calling ‘loss of
staining’ in the tumor cells.
It is advisable not to use ‘positive’ or ‘negative’ when
reporting MMR IHC results. In the case of MMR IHC,
positive (presence of) staining is a normal result, while
negative (lack of) staining is abnormal and suggests the
need for further testing. Therefore, the conventional
“positive” and “negative” descriptors can be confusing and
should be avoided in MMR IHC reports. We prefer to use
the terminology “intact” when tumor nuclei show staining,
and “loss” when tumor nuclei lack staining and this lan-
guage is used in the College of American Pathologists
(CAP) biomarker protocol [64].
As discussed previously, the pairing and dimerization
of the MMR proteins stabilize the function unit, which
help to explain the staining pattern of MMR expression/
loss observed. Figures 2 and 3 demonstrate two cases
with abnormal MMR IHC results. Figure 2 demonstrates
MMR IHC in a patient with sporadic hypermethylation
of the MLH1 promoter, in which both MLH1 and PMS2
show loss of expression. Figure 3 demonstrates MMR
IHC in a patient with LS with isolated loss of MSH6.
When all four MMR proteins are absent, the possibil-
ity of poor fixation and loss of antigenicity should be
considered. The surrounding stroma is an excellent
positive control and should always show staining. On
the other hand, intact expression of all four proteins
does not exclude LS. About 5% of families harbor a
missense mutation (most commonly in MLH1) that re-
sults in a nonfunctional protein with retained antigenicity.
Unusual Patterns That Can Lead to Confusion
 In cases of isolated loss of PMS2 IHC, germline
MLH1 analysis should be performed if no mutations
are detected through PMS2 testing. In a study by
Dudley et al [65], approximately 24% of patient with
tumors with isolated loss of PMS2 expression harbor
germline MLH1 mutation. Furthermore, a subset of
MLH1 mutations result in functionally inactive MLH1
protein that is antigenically intact and will be detected
by the commonly used anti-MLH1 antibody clones.
Such germline MLH1 mutations will lead to decreased
MLH1 protein stability and/or quantity, compromised
stability of MLH1-PMS2 complexes, and subsequent
PMS2 degradation. Recently, Rosty et al. [66]
Fig. 2 Immunohistochemistry for mismatch repair proteins in a patient with sporadic hypermethylation of the MLH1 promoter. Hematoxylin &
eosin (H&E) stain of the adenocarcinoma (a). Tumor cells show loss of MLH1 nuclear expression (b) and loss of PMS2 nuclear expression (c) while
the stroma and lymphocytes shows strong intact staining. Conversely, tumor cells show intact nuclear expression of MSH2 (d) and MSH6 (e). This
tumor showed BRAF V600E mutation by PCR consistent with sporadic microsatellite-unstable colorectal carcinoma
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demonstrated similar findings, and they also
recommend germline MLH1 mutation analysis
in individuals with isolated loss of PMS2 expression
but without PMS2 mutation identified.
 Very rarely, all four stains are lost (null pattern) due
to a germline MSH2 mutation (causing absent MSH2/
MSH6) together with a somatic MLH1
hypermethylation (causing absent MLH1/PMS2) [67].
 Another uncommon finding is loss of MSH6
together with MLH1 and PMS2. This could occur
due to MLH1 promoter hypermethylation causing
MLH1/PMS2 loss, leading to MSI. Such MLH1/
PMS2 deficient, MSI tumors, are prone to generate
somatic mutations in MSH6 gene, which cause
significantly reduced staining of MSH6 [68].
FAQs for MMR immunohistochemistry
1. A patient’s colon cancer was previously screened for
LS and no abnormality was found, should I screen a
second colon or endometrial cancer in this patient?
Answer: MMR IHC of synchronous/metachronous
neoplasms in LS patients demonstrated discordant
MMR immunoreactivity in 31% cases [69], therefore
it may be worthwhile to perform LS screening in all
primary, synchronous, and metachronous LS-
associated neoplasms if a previous tumor
screened intact.
2. A Gastroenterologist asked to test MMR IHC in
an adenoma, how should I proceed for the IHC
interpretation?
Answer: The criteria for interpreting MMR IHC in
an adenoma are the same as for cancer. It has been
shown that 50% to 72% of conventional adenomas
from mutation carriers show loss of MMR protein
expression concordant with the underlying germline
mutation [70, 71]. In addition, the absence of staining
was particularly frequent in larger adenomas in LS
patients, was associated with adenomas with villous
component, and was observed more often in adenoma
with high-grade dysplasia. However, some adenomas
in LS patients only contain loss of one allele and do
not contain the second hit; and therefore still
demonstrate preserved MMR protein expression. In
signing out these cases we comment that “whereas
absent staining may be seen in LS and the pattern of
loss useful in directing gene testing, intact expression
does not exclude the diagnosis.”
3. Does neoadjuvant therapy in rectal cancer affect
MMR IHC result?
Answer: Rectal tumors treated with neoadjuvant
therapy can sometimes show decreased or complete
loss of MSH6 staining or only a nucleolar staining
pattern (Fig. 4) [72, 73]. Evidence has shown that
most of these cases do not have a MSH6 mutation
Fig. 3 Immunohistochemistry for mismatch repair proteins in a patient with Lynch syndrome. H&E stain of the mucinous adenocarcinoma (a).
Intact nuclear expression of MLH1 (b) and PMS2 (c). Intact nuclear expression of MSH2 (d). This tumor showed absent nuclear staining of MSH6
(e). Genetic sequencing confirmed mutation of the MSH6 gene
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and this should not be interpreted as loss/absence
of MSH6. Rather than immediately sequencing
questionable cases, repeating the IHC or performing
IHC on the pretreatment biopsy will help resolve
this issue. Decreased expression of PMS2 has also
been reported in 30% of posttreatment rectal
carcinomas [74]
4. Can MMR IHC be performed on autopsy cases?
Answer: Yes, MMR IHC may be performed on autopsy
cases, but be aware of the inferior preservation of the
tumor tissue in autopsy cases, which may lead to weak
and patchy nuclear staining of the tumor cells.
Nonetheless, if the internal control (adjacent benign
epithelium, stroma or background lymphocytes)
demonstrates similar weak staining, it is most likely
that the MMR protein expression is intact/normal.
5. Can MMR IHC be performed on metastasis?
Answer: Our group recently demonstrated [75] that
in 50 primary CRC with metastasis, there is 100%
concordance of MMR IHC results between primary
and metastasis, suggesting that using metastatic tissue
to identify patients with dMMR tumors (screen for LS
or to aid in therapeutic choices) is feasible when the
primary tissue is not available for testing.
6. Should MMR IHC be performed on serrated polyps
to help exclude LS?
Answer: No. CRC arising from the serrated pathway
has different underlying molecular genetics than
CRC arising from LS [76], although both may show
dMMR. The genetic signature of CRC arising from
serrated polyps often contains BRAF mutation and
MLH1 promoter hypermethylation. In contrast, LS
almost never harbors BRAF mutation.
Conclusions
Detecting LS is desirable because intensified clinical can-
cer surveillance saves lives. Identification of MSI CRC is
important, as dMMR may serve as a screening tool for
detecting LS, a prognostic marker for patient outcome,
and a predictive marker for response to chemotherapy.
Tumor DNA sequencing should be undertaken in un-
solved cases of abnormal LS screening without identifi-
able germline mutation, to evaluate for somatic biallelic
mutations, as it can explain two thirds of these cases
and help guide genetic counseling and reduce patient
anxiety. Next generation sequencing methodology has
been employed for detection of molecular alterations in
dMMR CRC and may replace the current method of de-
tecting MSI by PCR techniques in the near future.
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